Johnson & Johnson has shaken-hands on a most-favoured-nation (MFN) drug pricing deal with the Trump administration.
With the agreement—which frees J&J up from tariffs on imported products—the company will offer some of its drugs at lower prices through the government’s direct-to-consumer platform, TrumpRx.gov.
J&J’s deal comes three weeks after President Donald Trump announced similar arrangements with nine other pharma majors: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Merck, Novartis, Roche’s Genentech and Sanofi. Earlier last year, AstraZeneca, Merck KGaA’s EMD Serono, Pfizer, Eli Lilly and Novo Nordisk also struck MFN deals with the administration.
The New Jersey company did not specify which products would be included or how much they would be discounted, other than to say they would be available at prices that were “comparable” to other developed countries. The same standard applies to medicines J&J will provide through the Medicaid program, it said.
Along with the deal, the company unveiled plans to build a cell therapy plant in Pennsylvania and a drug product manufacturing facility in North Carolina.
J&J did not reveal the exact location of the Pennsylvania site or how much it plans to spend on its construction.
Meanwhile, in a release, North Carolina Gov. Josh Stein revealed that J&J’s new facility would be in Wilson, N.C., where it already has a site under construction. The newly announced plant will create 500 manufacturing jobs.
All of the sites fall under the company’s commitment to invest $55 billion in bolstering its U.S. manufacturing, R&D and medtech capabilities by early 2029, which it announced last year.
